Solventum Corporation (SOLV)
Solventum is a healthcare company that spun off from 3M, focusing on medical supplies like wound care, dental products, and health information technology.
Is Solventum Corporation a good stock for a UK beginner?
The honest version: There's no rating here and nothing for sale. In its favour: Strong profit margins on core products. Worth weighing: Recent decline in revenue and earnings.
Is this normal for this company?
Each figure against the range this same company has produced recently. Neither end of a range is the good end.
Share price divided by the earnings actually reported over the four most recent quarters. The range is the same calculation at each of this company's last few results, so roughly the past year.
Profit as a share of sales, from the company's own quarterly statements. The range covers the 5 quarters we hold, and the figure shown is its most recent one.
How these ranges are built
Every number here is the company's own reported figure, not a comparison with other companies. The ranges come from this company's own results and its share price. Where it reports in a different currency from the one its shares trade in, the price-to-earnings range is left out rather than mixing the two.
What does Solventum Corporation do?
Solventum operates as a standalone business after separating from the industrial giant 3M, selling essential medical equipment and software to hospitals and clinics. Revenue comes from selling high-volume medical consumables and digital health tools that doctors rely on daily. How smoothly they handle life as a newly independent company, while trying to return to consistent growth, is what to keep an eye on.
On our factor screen it looks strongest on value and momentum, and weakest on income.
- !Pays no dividend - the whole return rides on the share price
- ✓Growing - revenue up about 2% over the year
- ✓Very profitable - turns about 17% of sales into profit
- ·Low P/E of 10 vs last year's earnings
- ✓Strong return on shareholder money (ROE 34%)
- —
- Growth screens low
- Income screens low
Does Solventum Corporation pay a dividend?
No - Solventum Corporation doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
Does Solventum Corporation have more cash or more debt?
It holds about $403.00M in cash against about $5.30B of debt - so it has net debt of about $4.89B. Debt is not automatically a problem - it funds growth - but it has to be serviced and repaid, which matters more when profits wobble.
From the latest reported balance sheet. Cash and debt levels change, and some borrowing is normal - this is context, not a judgment.
What do Solventum Corporation's numbers mean?
How has it performed?
Growth of £1,000, the worst fall, and year by year
Over about 2 years to 2026-09-11. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
How much has Solventum Corporation actually fallen?
Over the last 2 years of daily prices, Solventum Corporation fell as much as −27% from a high to a later low. Falls like this are normal when you own a share.
Past falls are not a forecast - it can fall further, or recover.
How has it done year by year?
Calendar-year total return - the share price with dividends reinvested - from adjusted closing prices. The current year is only part-complete. Past returns are not a guide to the future.
A closer look at the numbers
Ownership, earnings history, where the money goes, and the outlook range
Does the share price tell you if it's cheap or expensive?
Who owns Solventum Corporation?
About 76% of Solventum Corporation, or about 76 in every 100 shares, is held by big institutions such as pension and index funds, and company insiders hold about 15%. The rest, roughly 9%, is held by the public and smaller investors.
What this does and doesn't tell you
This is a recent snapshot of the share register, and it moves. We don't read anything into who owns what - a high institutional share is common for any large listed company and is not a signal about it.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
How much money does Solventum Corporation make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Where does each £100 of Solventum Corporation's sales go?
A rough split of the latest full-year figures: of every £100 of sales, about £45 covers making the product or service, £38 goes on running costs, tax and interest, and about £17 is left as profit. Margins vary a lot by industry, and one-off items can distort a single year.
When does Solventum Corporation report earnings, and how did recent quarters go?
Solventum Corporation is next scheduled to report on about 2026-11-05 - dates can move, and we don't predict results; this just tells you when to look.
‘Beat’ and ‘missed’ are against what analysts expected, not whether the business is doing well.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-05-05 | $1.35 | $1.48 | Beat +9% |
| 2026-02-26 | $1.50 | $1.57 | Beat +5% |
| 2025-11-06 | $1.43 | $1.50 | Beat +5% |
| 2025-08-07 | $1.45 | $1.69 | Beat +16% |
| 2025-05-08 | $1.22 | $1.34 | Beat +10% |
| 2025-02-27 | $1.31 | $1.41 | Beat +8% |
Across the last 6 quarters here, Solventum Corporation came in ahead of what analysts expected 6 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Where these figures come from
Each quarter a company reports its results against a consensus of analyst forecasts. The figures here are reported versus expected earnings per share from published results; the expectation is that analyst consensus, not our view. Report dates are estimates and can move.
What are the scenarios for Solventum Corporation?
An illustrative range for the year ahead — not a prediction or a price target.
What are the pros, cons and common questions?
The case each way, and the questions people ask
Successful pivot to high-growth digital health solutions.
Failure to compete effectively in the medical tech space.
What are the pros and cons of Solventum Corporation?
A balance check, not a score or verdict.
- Strong profit margins on core products
- Essential nature of medical supplies
- Lower volatility compared to the broader market
- Recent decline in revenue and earnings
- No dividend payments to shareholders
- Uncertainty following the recent spin-off
- High competition in the medical device sector
- Potential for ongoing restructuring costs
- Regulatory changes affecting healthcare spending
The write-up's own warning lights — if these start happening, the case above changes.
- A sustained return to positive revenue growth
- Significant improvement in earnings performance
Common questions about Solventum Corporation
Does Solventum Corporation pay a dividend?
No - Solventum Corporation does not currently pay a dividend, so the return would rest on the share price. Many growing companies reinvest profits instead of paying them out.
When does Solventum Corporation report earnings next?
Solventum Corporation is next scheduled to report results on about 2026-11-05. Report dates are estimates and can move; this is a diary note for when to look, not a forecast of the outcome.
More in Healthcare
IDEXX Laboratories, Inc.
Charles River Laboratories International, Inc.
Baxter International Inc.
GSK
Haleon plc
AstraZeneca PLC
Convatec Group PLC
Beam Therapeutics Inc.Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-02 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.